Gyre Therapeutics Inc. Cash Flow Conversion Efficiency
Gyre Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.18 Million) by net assets ($136.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Gyre Therapeutics Inc. (2004–2025)
Cash flow conversion efficiency of Gyre Therapeutics Inc. from 2004 to 2025. This chart illustrates how Gyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View GYRE live share price for real-time trading data and today's change.
Gyre Therapeutics Inc. Cash Flow Conversion Ratio Explained
Gyre Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Gyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gyre Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see GYRE company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.018x |
|
C&C Group PLC
F:GCC
|
0.023x |
|
Beijing Jingpin Tezhuang Technology Co. Ltd. A
SHG:688084
|
N/A |
|
Petpal Pet Nutrition Technology Co Ltd
SHE:300673
|
0.013x |
|
Shenzhen Bestek Technology Co Ltd
SHE:300822
|
0.014x |
|
Bénéteau S.A.
PA:BEN
|
-0.032x |
|
Shenzhen Huijie Group Co Ltd
SHE:002763
|
0.048x |
|
Better Home & Finance Holding Company
NYSE:BETR
|
-0.797x |
Annual Cash Flow Conversion Efficiency for Gyre Therapeutics Inc. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Gyre Therapeutics Inc. from 2004 to 2025. Review GYRE FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $142.28 Million | $1.01 Million | 0.007x | +119.18% |
| 2024-12-31 | $98.40 Million | $-3.64 Million | -0.037x | -101.99% |
| 2023-12-31 | $13.95 Million | $25.89 Million | 1.856x | +1155.49% |
| 2022-12-31 | $72.22 Million | $10.68 Million | 0.148x | +107.25% |
| 2021-12-31 | $41.09 Million | $-83.75 Million | -2.038x | -181.68% |
| 2020-12-31 | $76.07 Million | $-55.05 Million | -0.724x | -13.39% |
| 2019-12-31 | $68.34 Million | $-43.61 Million | -0.638x | -168.10% |
| 2018-12-31 | $119.94 Million | $-28.55 Million | -0.238x | +63.26% |
| 2017-12-31 | $30.77 Million | $-19.94 Million | -0.648x | +43.63% |
| 2016-12-31 | $16.07 Million | $-18.47 Million | -1.149x | -88.93% |
| 2015-12-31 | $31.43 Million | $-19.12 Million | -0.608x | -92.45% |
| 2014-12-31 | $109.08 Million | $-34.48 Million | -0.316x | -4.78% |
| 2013-12-31 | $134.61 Million | $-40.61 Million | -0.302x | +17.38% |
| 2012-12-31 | $175.91 Million | $-64.24 Million | -0.365x | +23.98% |
| 2011-12-31 | $174.29 Million | $-83.72 Million | -0.480x | -131.90% |
| 2010-12-31 | $91.85 Million | $138.30 Million | 1.506x | +528.01% |
| 2009-12-31 | $68.99 Million | $-24.27 Million | -0.352x | +28.58% |
| 2008-12-31 | $57.37 Million | $-28.26 Million | -0.493x | -202.30% |
| 2007-12-31 | $51.58 Million | $24.84 Million | 0.482x | +416.38% |
| 2006-12-31 | $65.00 Million | $-9.89 Million | -0.152x | -194.22% |
| 2005-12-31 | $-162.48 Million | $-26.25 Million | 0.162x | -20.66% |
| 2004-12-31 | $-122.97 Million | $-25.04 Million | 0.204x | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more